Literature DB >> 4923653

L-dopa in Parkinsonism and the influence of previous thalamotomy.

R C Hughes, J G Polgar, D Weightman, J N Walton.   

Abstract

A double-blind cross-over trial over 24 weeks (10 weeks on the active remedy, 4 weeks off treatment, and 10 weeks on placebo) of the effect of L-dopa on idiopathic Parkinsonism (paralysis agitans) has shown no difference in the response obtained in patients who had undergone previous stereotaxic ventrolateral thalamotomy and in those who had not. Of the 34 patients (18 men and 16 women) in the trial 18 had been operated on (nine unilateral, nine bilateral operations) and 16 had not. All patients entering the trial were taking anticholinergic drugs in stable dosage and these were continued throughout. The only factor which seemed to limit the response to treatment was pre-existing hypertension. Of 31 patients who completed the 10-week treatment period, 12 showed marked improvement, 15 moderate improvement, and 4 and mild or negligible change. It seems that previous ventrolateral thalamotomy affords some protection against the development of L-dopa-induced involuntary limb movements on the side contralateral to the operation. As found by others, maximum benefit was seen in bradykinesia and rigidity and related features but a significant reduction in tremor was also noted during treatment. Side effects (nausea, hypotension, and involuntary movements) were common but rarely limited the therapeutic response.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4923653      PMCID: PMC1794736          DOI: 10.1136/bmj.1.5739.7

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  13 in total

1.  Dopamine metabolism in Parkinson's disease.

Authors:  M GREER; C M WILLIAMS
Journal:  Neurology       Date:  1963-01       Impact factor: 9.910

2.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

3.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

4.  L-dopa in postencephalitic parkinsonism.

Authors:  D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

5.  Reversal of the glabellar reflex in Parkinsonism by L-dopa.

Authors:  H L Klawans; J A Goodwin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-10       Impact factor: 10.154

6.  L-dopa in the treatment of Parkinsonism; a preliminary appraisal.

Authors:  S Stellar; S Mandell; J M Waltz; I S Cooper
Journal:  J Neurosurg       Date:  1970-03       Impact factor: 5.115

7.  Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.

Authors:  A Barbeau
Journal:  Neurology       Date:  1970-04       Impact factor: 9.910

8.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

9.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704

10.  Treatment of Parkinsonism with Laevo-dopa.

Authors:  C Mawdsley
Journal:  Br Med J       Date:  1970-02-07
View more
  14 in total

1.  Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.

Authors:  A Fredriksson; N Schröder; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

2.  Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.

Authors:  A Fredriksson; W Danysz; G Quack; T Archer
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 3.  The use of thalamotomy in the treatment of levodopa-induced dyskinesia.

Authors:  R D Page
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

Review 4.  The treatment of Parkinson's disease.

Authors:  R B Godwin-Austen
Journal:  Postgrad Med J       Date:  1977-12       Impact factor: 2.401

5.  The comparative value of amantadine and levodopa.

Authors:  V Dallos; K Heathfield; P Stone; F Allen
Journal:  Postgrad Med J       Date:  1972-06       Impact factor: 2.401

Review 6.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

7.  Treatment of Parkinson's syndrome with L-DOPA on an out-patient basis.

Authors:  C Fehling
Journal:  Z Neurol       Date:  1972

8.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

9.  [Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].

Authors:  W Gehlen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974-04-09

10.  Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa.

Authors:  R B Godwin-Austen; S Bergmann; C C Frears
Journal:  Br Med J       Date:  1971-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.